{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:28:05Z","timestamp":1785234485590,"version":"3.55.0"},"reference-count":30,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Development Research"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Lifitegrast is a lymphocyte function\u2010associated antigen\u20101 (LFA\u20101) antagonist, which is approved for treatment of dry eye disease. In this work we explored the effect of lifitegrast in imiquimod induced psoriasis model in mice. Lifitegrast (5% solution) was tested in imiquimod\u2010induced psoriasis model in C57 mice. Lifitegrast was topically administered twice a day to the psoriatic skin for 6 days and epidermal skin thickness, psoriasis area and severity index (PASI) score and inflammation markers were assessed. Lifitegrast inhibited the imiquimod\u2010induced increase in the epidermal thickness, histopathological changes and PASI score. This decrease in psoriasis inflammation was accompanied by decrease in TNF\u2010\u03b1, IL\u20106, IL\u201022 and IL\u201017\/IL\u201023 axis gene expression in the skin, and the effect is comparable to the oral cyclosporine A(5\u2009mg\/kg, twice a day) treatment. Lifitegrast demonstrated significant anti\u2010inflammatory activity, mainly through reduction in cytokine gene expression related to psoriasis and decreased the severity of psoriasis in vivo. The significant effect shown by this LFA\u20101 and ICAM\u20101 antagonist indicates a novel topical treatment for psoriasis.<\/jats:p>","DOI":"10.1002\/ddr.70034","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T04:04:51Z","timestamp":1734321891000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lifitegrast, a Lymphocyte Function\u2010Associated Antigen\u20101 Antagonist Demonstrates Beneficial Effect in Psoriasis"],"prefix":"10.1002","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3243-8743","authenticated-orcid":false,"given":"Rahul Sudhakar","family":"Gawande","sequence":"first","affiliation":[{"name":"Datta Meghe College of Pharmacy, DMIHER (M) Sawangi India"},{"name":"Orbicular Pharmaceutical Technologies Pvt Ltd. ALEAP Industrial Area, Behind Pragati Nagar Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Rao Thakkalapally","sequence":"additional","affiliation":[{"name":"Orbicular Pharmaceutical Technologies Pvt Ltd. ALEAP Industrial Area, Behind Pragati Nagar Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil M.","family":"Pethe","sequence":"additional","affiliation":[{"name":"Datta Meghe College of Pharmacy, DMIHER (M) Sawangi India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.063"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000961"},{"issue":"3","key":"e_1_2_6_4_1","first-page":"301","article-title":"Efalizumab in the Treatment of Psoriasis","volume":"1","author":"Boehncke W. H.","year":"2007","journal-title":"Biologics: Targets & Therapy"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(98)01381-4"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147960"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(92)70012-5"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v29.i2.10"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669400"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000803"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.09.281"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2015.27.1.26"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2005.08.019"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11175014"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810844106"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137890"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2005.12.029"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.717042"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05663"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90104-8"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12106"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-5078"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65109-7"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12276285"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2016.01.001"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2016.0105"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(00)00347-X"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-5144"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158437"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1081256"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-078154"}],"container-title":["Drug Development Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.70034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T16:34:22Z","timestamp":1760373262000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/ddr.70034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/ddr.70034"],"URL":"https:\/\/doi.org\/10.1002\/ddr.70034","archive":["Portico"],"relation":{},"ISSN":["0272-4391","1098-2299"],"issn-type":[{"value":"0272-4391","type":"print"},{"value":"1098-2299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70034"}}